Zacks: Analysts Anticipate Chimerix Inc. (CMRX) Will Announce Quarterly Sales of $940,000.00

Brokerages expect Chimerix Inc. (NASDAQ:CMRX) to post sales of $940,000.00 for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Chimerix’s earnings, with the highest sales estimate coming in at $1.45 million and the lowest estimate coming in at $500,000.00. Chimerix reported sales of $680,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 38.2%. The firm is expected to report its next earnings report on Monday, August 6th.

On average, analysts expect that Chimerix will report full year sales of $3.59 million for the current financial year, with estimates ranging from $2.29 million to $5.07 million. For the next financial year, analysts forecast that the company will post sales of $10.75 million per share, with estimates ranging from $3.20 million to $25.00 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Chimerix.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Monday, May 7th. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.01. Chimerix had a negative net margin of 1,736.95% and a negative return on equity of 31.97%. The business had revenue of $0.79 million during the quarter, compared to analysts’ expectations of $1.12 million.

CMRX has been the subject of a number of recent research reports. Cowen reissued a “hold” rating and issued a $6.00 price objective on shares of Chimerix in a research note on Thursday, March 1st. BidaskClub raised shares of Chimerix from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 15th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Chimerix in a research note on Monday, March 19th. Zacks Investment Research cut shares of Chimerix from a “hold” rating to a “sell” rating in a research note on Monday, January 22nd. Finally, ValuEngine raised shares of Chimerix from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Two research analysts have rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $7.08.

In related news, Director Ernest Mario sold 30,000 shares of Chimerix stock in a transaction dated Wednesday, May 16th. The shares were sold at an average price of $4.79, for a total transaction of $143,700.00. Following the completion of the transaction, the director now directly owns 12,905 shares of the company’s stock, valued at approximately $61,814.95. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 85,368 shares of company stock valued at $400,495. 12.50% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Quantitative Systematic Strategies LLC purchased a new position in shares of Chimerix during the 1st quarter worth about $115,000. MetLife Investment Advisors LLC purchased a new position in shares of Chimerix during the 1st quarter worth about $127,000. Goldman Sachs Group Inc. purchased a new position in shares of Chimerix during the 4th quarter worth about $137,000. Wells Fargo & Company MN boosted its stake in shares of Chimerix by 46.1% during the 1st quarter. Wells Fargo & Company MN now owns 33,569 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 10,598 shares during the period. Finally, A.R.T. Advisors LLC bought a new stake in Chimerix during the 1st quarter valued at about $252,000. 74.73% of the stock is owned by hedge funds and other institutional investors.

Shares of Chimerix opened at $4.80 on Friday, MarketBeat.com reports. Chimerix has a 52 week low of $4.73 and a 52 week high of $4.81.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply